RGEN Repligen Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN
  4. Earnings
?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 66

EPS in 2026 (TTM): $0.92

Last Report Period Date: Mar 31, 2026

According to the most recent financial data from March 2026, the EPS for the trailing twelve months is $0.92. Repligen's EPS for 2025 amounted to $0.87, marking an increase from -$0.46 in 2024. During the quarterly period ending on Mar 31, 2026, RGEN's EPS stood at $0.15.

RGEN earnings history

Historical annual and quarterly earnings per share (EPS) data for Repligen
EPS (TTM)
$0.92
EPS Growth YoY (Quarterly)
50%
EPS (Quarterly)
$0.15
EPS Growth (Quarterly)
-37.5%

Repligen had an annual EPS of $0.87, indicating an increase of 289.1% from -$0.46 in 2024. The quarterly per-share earnings for the period ending Mar 31, 2026, was $0.15, indicating a 50% increase from the same quarter last year. RGEN's 12-month EPS stands at $0.92 as of March 2026. Repligen's annual EPS in 2024 stood at -$0.46, a 171.9% decrease year-over-year.

RGEN earnings chart

RGEN EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
50%
EPS growth YoY
289.1%
EPS growth 3Y avg
-36.2%
EPS growth 5Y avg
-5.3%

Repligen has registered an increase in EPS of 50% during the last 12 months (YoY, quarterly). In the last three years, RGEN recorded an average annual EPS growth rate of -36.2%. Repligen had an average annual EPS growth rate of -5.3% during the last 5 years. Across the last decade, RGEN had an average annual EPS growth of 12%.

RGEN Earnings Waterfall

Breakdown of revenue, profit and net income for Repligen

RGEN Earnings vs Peers

What are the earnings of RGEN compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 15.55 178.7% 5.3% N/A
PFE Pfizer Inc 18.87 -3.5% -37.4% -3.7%
NBIX Neurocrine Biosciences Inc 24.06 41.5% 44% 1.9%
TMO Thermo Fisher Scientific Inc 25.76 7.2% 0% 2%
BMRN Biomarin Pharmaceutical Inc 40.36 -19.1% 33.8% -17.4%
GE General Electric Co 43.58 35.8% 447.4% 12.1%
TECH BIO-TECHNE Corp 79.24 -56.1% -35.2% -20.7%
RGEN Repligen Corp 137.36 289.1% -36.2% -5.3%
NVAX Novavax Inc N/A 321.1% N/A N/A
CRL Charles River Laboratories International Inc N/A -1,555% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.